Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 6/20 | 0.51 |
| ▸ | ACHE | P22303 | 3/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.45 |
| ▸ | KDM1A | O60341 | 1/20 | 0.45 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.45 |
| ▸ | RCOR1 | Q9UKL0 | 1/20 | 0.45 |
| ▸ | DNMT3A | Q9Y6K1 | 2/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.45 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4117068 | 0.99 | ESR1 (0.51) | ESR1ACHEHRH3LTA4HKDM1A | |
| SCHEMBL4767566 | 0.99 | ESR1 (0.50) | ESR1ACHEHRH3LTA4HKDM1A | |
| Hydrochloric Acid SCHEMBL4129891 | 0.98 | ESR1 (0.49) | ESR1ACHEHRH3LTA4HKDM1A | |
| SCHEMBL4764004 | 0.96 | HRH3 (0.51) | ACHEHRH3KDM1AEHMT2RCOR1 | |
| Hydrochloric Acid SCHEMBL4130821 | 0.95 | HRH3 (0.50) | ACHEHRH3KDM1AEHMT2RCOR1 | |
| SCHEMBL5193700 | 0.92 | ACHE (0.56) | ACHEKDM1AEHMT2RCOR1DNMT3A | |
| SCHEMBL4765657 | 0.92 | ACHE (0.47) | ESR1ACHEHRH3KDM1AEHMT2 | |
| Hydrochloric Acid SCHEMBL4838721 | 0.92 | ACHE (0.55) | ACHEKDM1AEHMT2RCOR1DNMT3A | |
| Hydrochloric Acid SCHEMBL4124956 | 0.91 | ACHE (0.47) | ESR1ACHEHRH3KDM1AEHMT2 | |
| SCHEMBL5196850 | 0.90 | ACHE (0.58) | ACHEEHMT2DNMT3AMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940823-A2 | SUBSTITUTED 1-AMINO-PHTHALZINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2008-07-09 | — | — | EP | claimed |
| WO-2007042660-A2 | SUBSTITUTED 1-AMINO-PHTHALZINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-04-19 | — | — | WO | claimed |
| US-20090124624-A1 | SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-05-14 | — | — | US | disclosed |
| US-20090124624-A1 | SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | SANOFI-AVENTIS (FR) | 2009-05-14 | — | — | US | disclosed |
| EP-1940823-A2 | SUBSTITUTED 1-AMINO-PHTHALZINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | Sanofi-Aventis (FR) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007042660-A2 | SUBSTITUTED 1-AMINO-PHTHALZINE DERIVATIVES, PREPARATION AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090124624-A1 | SUBSTITUTED 1-AMINOPHTHALAZINE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC APPLICATION THEREOF | AGTR1, AGTR2, AHR | ESR1 2142/4885ACHE 2862/4885HRH3 165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.